Jan 25, 2019 - Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Jan 24, 2019 - Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.
Jan 24, 2019 - The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.
Jan 21, 2019 - Top Analyst Reports for Bank of America, Merck & Netflix
Jan 21, 2019 - Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
Jan 16, 2019 -
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week highs Jan. 15)
Jan 15, 2019 - A new law requiring pharmaceuticals companies to test cancer drugs on children as well as adults is raising hopes of more therapies.
Jan 15, 2019 - ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.U.S. biosimilars to Humira will enter in 2023, though a competitor is tr
Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.